Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093320
Filing Date
2024-08-08
Accepted
2024-08-08 07:20:06
Documents
58
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cgem-20240630.htm   iXBRL 10-Q 1432087
2 EX-31.1 cgem-ex31_1.htm EX-31.1 13698
3 EX-31.2 cgem-ex31_2.htm EX-31.2 13489
4 EX-32.1 cgem-ex32_1.htm EX-32.1 12391
  Complete submission text file 0000950170-24-093320.txt   6166412

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20240630.xsd EX-101.SCH 1100670
61 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20240630_htm.xml XML 850609
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813867811 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39856 | Film No.: 241186041
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)